JP2021517146A5 - - Google Patents
Info
- Publication number
- JP2021517146A5 JP2021517146A5 JP2020547393A JP2020547393A JP2021517146A5 JP 2021517146 A5 JP2021517146 A5 JP 2021517146A5 JP 2020547393 A JP2020547393 A JP 2020547393A JP 2020547393 A JP2020547393 A JP 2020547393A JP 2021517146 A5 JP2021517146 A5 JP 2021517146A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- pharmaceutical composition
- phenyl
- hydrogen
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023202431A JP7830412B2 (ja) | 2018-03-14 | 2023-11-30 | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841009306 | 2018-03-14 | ||
| IN201841009306 | 2018-03-14 | ||
| PCT/IB2019/052039 WO2019175799A2 (en) | 2018-03-14 | 2019-03-13 | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202431A Division JP7830412B2 (ja) | 2018-03-14 | 2023-11-30 | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517146A JP2021517146A (ja) | 2021-07-15 |
| JP2021517146A5 true JP2021517146A5 (https=) | 2022-03-16 |
| JPWO2019175799A5 JPWO2019175799A5 (https=) | 2022-03-16 |
| JP7417804B2 JP7417804B2 (ja) | 2024-01-19 |
Family
ID=67907451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547393A Active JP7417804B2 (ja) | 2018-03-14 | 2019-03-13 | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 |
| JP2023202431A Active JP7830412B2 (ja) | 2018-03-14 | 2023-11-30 | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202431A Active JP7830412B2 (ja) | 2018-03-14 | 2023-11-30 | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210379024A1 (https=) |
| EP (1) | EP3768259A4 (https=) |
| JP (2) | JP7417804B2 (https=) |
| KR (1) | KR102940324B1 (https=) |
| CN (2) | CN111836621A (https=) |
| BR (1) | BR112020018555A2 (https=) |
| EA (1) | EA202091773A1 (https=) |
| MX (2) | MX2020009443A (https=) |
| WO (1) | WO2019175799A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019175799A2 (en) * | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| ES2747357T3 (es) | 2001-03-14 | 2020-03-10 | Dako Denmark As | Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| CA2916681A1 (en) * | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| HRP20181052T1 (hr) * | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| WO2015088847A1 (en) | 2013-12-11 | 2015-06-18 | Glaxosmithkline Llc | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| RS63295B1 (sr) | 2013-12-24 | 2022-06-30 | Janssen Pharmaceutica Nv | Anti-vista antitela i fragmenti |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| NZ734650A (en) | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| EP3267985A4 (en) * | 2015-03-10 | 2018-07-25 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| WO2018047143A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| MY205585A (en) * | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| AU2018360386B2 (en) * | 2017-11-03 | 2023-11-09 | Aurigene Oncology Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
| WO2019175799A2 (en) * | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
-
2019
- 2019-03-13 WO PCT/IB2019/052039 patent/WO2019175799A2/en not_active Ceased
- 2019-03-13 CN CN201980018382.1A patent/CN111836621A/zh active Pending
- 2019-03-13 MX MX2020009443A patent/MX2020009443A/es unknown
- 2019-03-13 BR BR112020018555-8A patent/BR112020018555A2/pt unknown
- 2019-03-13 EP EP19767288.4A patent/EP3768259A4/en active Pending
- 2019-03-13 EA EA202091773A patent/EA202091773A1/ru unknown
- 2019-03-13 US US17/045,916 patent/US20210379024A1/en active Pending
- 2019-03-13 CN CN202410341475.0A patent/CN118236374A/zh active Pending
- 2019-03-13 KR KR1020207026540A patent/KR102940324B1/ko active Active
- 2019-03-13 JP JP2020547393A patent/JP7417804B2/ja active Active
-
2020
- 2020-09-10 MX MX2023010303A patent/MX2023010303A/es unknown
-
2023
- 2023-11-22 US US18/518,292 patent/US12005045B2/en active Active
- 2023-11-30 JP JP2023202431A patent/JP7830412B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517146A5 (https=) | ||
| JP2019532083A5 (https=) | ||
| ES2536903T3 (es) | Un soporte para un punto de salida de un cable | |
| FR2931713B1 (fr) | Bandes en alliage d'aluminium pour tubes d'echangeurs thermiques brases | |
| JP2017095457A5 (https=) | ||
| CN114072411A (zh) | 作为Wee1抑制剂的嘧啶衍生物 | |
| EA201070256A1 (ru) | Способ и промежуточные соединения для получения ингибиторов интегразы | |
| JP2019523752A5 (https=) | ||
| EP1813572A3 (en) | Process and apparatus for synthesis gas | |
| JP2020097577A5 (https=) | ||
| EP2730637A4 (en) | FLUORESCENT RARE ALUMINUM GRAIN SUBSTANCE AND LIGHT EMITTING DEVICE MANUFACTURED THEREFROM | |
| AR106491A1 (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
| JP2013501824A5 (https=) | ||
| BR112015009227B1 (pt) | tubo trocador de calor, trocador de calor e método para produzir um revestimento | |
| JP2009544602A5 (https=) | ||
| JP2021504430A5 (https=) | ||
| AR093877A1 (es) | Aparato y metodo para separar sales del agua | |
| AR094936A1 (es) | Suspensión para administración oral que comprende tolvaptán amorfo, y a un método para producirla | |
| JP2018538273A5 (https=) | ||
| JP2014532728A5 (https=) | ||
| RU2018132264A (ru) | Промежуточные продукты в синтезе эрибулина и соответствующие способы синтеза | |
| JP2015160954A5 (https=) | ||
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| CA2705673A1 (fr) | Adjuvant pour liant hydraulique | |
| MX392700B (es) | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |